Who we serve
Legacy DNA partners with mid-market healthcare leaders building in complex, regulated markets where clarity is hard won and trust is essential, such as healthtech, pharmacy, age tech, longevity, and women's health.
We partner with CEOs, growth leaders, and PE operators navigating moments where growth must become clearer, more defensible, and more repeatable.
As companies scale, growth becomes harder to explain, defend, and sustain. Buyers ask tougher questions. Boards expect sharper answers. What worked early no longer holds up under scrutiny.
Our role is consistent across every engagement. We help leadership teams close the gap between the value they know they have built and what the market actually understands and rewards.
We provide focused expertise where growth, credibility, and enterprise value intersect. We apply a human-led, AI-augmented operating model designed for rigor, not shortcuts.
Scaling women’s health companies with clarity, credibility, and enterprise discipline
Women’s health companies are addressing long-overlooked needs. Demand is real. Impact is meaningful. Yet growth often slows as expectations rise.
As companies scale, the burden of proof increases. Skepticism is louder. Value stories that resonated early stop landing cleanly with payers, partners, and investors.
Legacy DNA works with mid-market women’s health leaders navigating the tension between mission and market expectations.
You might be here if...
How we help
Built for leaders scaling women’s health platforms who need traction that holds up under scrutiny.
Helping age tech companies scale with empathy and enterprise readiness
Age tech companies serve aging adults, caregivers, and families at moments where trust and reliability matter deeply.
Growth often stalls not because the solution lacks value, but because buying is complex and fragmented.
Legacy DNA brings both professional expertise and lived experience to age tech.
You might be here if...
How we help:
Built for leaders improving aging at home, caregiving, and senior care experiences who need traction that holds up under scrutiny.
Scaling longevity companies with credibility, discipline, and enterprise readiness
Longevity sits at the intersection of healthcare, science, personalization, and human performance. The opportunity is massive. Scrutiny is rising just as quickly.
As the category matures, innovation alone is no longer enough. Credibility becomes the constraint.
Legacy DNA partners with mid-market longevity companies navigating the shift from early momentum to enterprise maturity.
The longevity reality
You might be here if...
How we help:
Built for leaders building mid-market longevity platforms who need traction that holds up under scrutiny.
Deep pharmacy expertise built for scale and scrutiny
Pharmacy is not a vertical to us. It is a discipline we have spent more than 15 years inside.
We have worked end to end across specialty pharmacy, infusion pharmacy, independent and retail pharmacy, pharmaceutical manufacturers, pharmacy GPOs, and PBMs.
As pharmacy organizations scale, growth becomes harder to explain and defend. Patient experience, adherence, and access directly impact revenue durability and valuation, yet are often underestimated by outsiders.
You might be here if...
How we help:
Built for specialty, infusion, and independent pharmacy leaders who need traction that holds up under scrutiny.
Turning healthtech innovation into adoption, traction, and enterprise value
Innovation alone does not create value in healthcare. Adoption does.
Many mid-market healthtech companies outgrow founder-led selling before they build repeatable adoption systems.
Legacy DNA helps healthtech leaders navigate this commercialization inflection point.
You might be here if...
How we help:
Built for healthtech leaders navigating commercialization inflection points who need traction that holds up under scrutiny.
